I'm curious to see the outcome if big pharma were to gain control of LL. Hopefully, its by one that doesn't have a large pipeline of drugs that would be hurt by the broad market applicable to LL. Otherwise, LL may be doomed to the shelf until the owner sees a big enough profit motive to let it out.